[1] Taylor DR, Pavord ID. Biomarkers in the assessment and management of airways diseases. Postgrad Med J, 2008, 84(998):628-634. [2] Jrres RA. Modelling the production of nitric oxide within the human airways.Eur Respir J, 2000, 16 (3):555-560. [3] Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest, 2010, 138(3):682-692. [4] Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med, 2005, 172 (4): 453-459. [5] Zacharasiewicz A, Wilson N, Lex C, et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med, 2005, 171 (10): 1077-1082. [6] Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med,2011, 184(5):602-615. [7] Kostikas K, Papaioannou AI, Tanou K, et al. Exhaled NO and exhaled breath condensate pH in the evaluation of asthma control. Respir Med, 2011, 105(4):526-532. [8] Murugan A, Prys-Picard C, Calhoun WJ. Biomarkers in asthma. Curr Opin Pulm Med, 2009, 15(1):12-18. [9] Caballero Balanzá S,Martorell Aragonés A,Cerdá Mir JC, et al. Leukotriene B4 and 8-isoprostane in exhaled breath condensate of children with episodic and persistent asthma. J Investig Allergol Clin Immunol, 2010, 20(3):237-243. [10] Teng Y, Sun P, Zhang J, et al. Hydrogen peroxide in exhaled breath condensate in patients with asthma: a promising biomarker? Chest, 2011, 140(1):108-116. [11] Gupta S, Siddiqui S, Haldar P, et al. Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes. Thorax,2010, 65(9):775-781. [12] Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest, 2009, 136(6):1521-1528. [13] Brillet PY, Attali V, Nachbaur G, et al. Multidetector row computed tomography to assess changes in airways linked to asthma control. Respiration, 2011, 81(6):461-468. [14] Soja J, Grzanka P, Sladek K, et al. The use of endobronchial ultrasonography in assessment of bronchial wall remodeling in patients with asthma. Chest, 2009, 136(3):797-804. [15] Fahy JV. Identifying clinical phenotypes of asthma: steps in the right direction. Am J Respir Crit Care Med, 2010, 181(4):296-297. [16] Cowan DC, Cowan JO, Palmay R, et al. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax, 2010, 65(5):384-390. [17] Woodruff PG, Modrek B, Choy DF,et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med, 2009, 180(5):388-395. [18] Gentile DA, Skoner DP. New asthma drugs: small molecule inhaled corticosteroids. Curr Opin Pharmacol, 2010, 10(3):260-265. [19] Vogelmeier CF, Hering T, Lewin T, et al. Efficacy and safety of ciclesonide in the treatment of 24 037 asthmatic patients in routine medical care. Respir Med, 2011, 105(2):186-194. [20] Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med, 2010, 363(18):1715-1726. [21] Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol, 2004, 114(4):851-857. [22] Calamita Z, Saconato H, Pelá AB, et al. Efficacy of sublingual immunotherapy in asthma: systematic review of rando-mized-clinical trials using the Cochrane Collaboration method. Allergy, 2006, 61(10):1162-1172. [23] Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol, 2010, 126(5):969-975. [24] Spector S. Omalizumab:efficacy in allergic disease. Panminerva Med, 2004, 46(2):141-148. [25] Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol, 2005, 115(3): 459-465. [26] Costello RW, Long DA, Gaine S, et al. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci, 2011, 180(3):637-641. [27] Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med, 2011, 184(10):1125-1132. [28] Gauvreau GM, Boulet LP, Cockcroft DW, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med, 2011, 183(8):1007-1014. [29] Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4 Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med, 2010, 181(8):788-796. [30] Castro M, Rubin A, Laviolette M, et al. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol,2011, 107(1):65-70. [31] Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med,2010, 181(2):116-124. [32] Sandhu MS, Casale TB. The role of vitamin D in asthma. Ann Allergy Asthma Immunol, 2010, 105(3):191-199. [33] Hollams EM, Hart PH, Holt BJ, et al. Vitamin D and atopy and asthma phenotypes in children: a longitudinal cohort study. Eur Respir J, 2011, 38(6):1320-1327. [34] Denning DW, O’Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization:The Fungal Asthma Sensitization Trial (FAST) Study. Am J Respir Crit Care Med, 2009, 179(1):11-18. [35] Cheung TK, Lam B, Lam KF, et al. Gastroesophageal reflux disease is associated with poor asthma control, quality of life, and psychological status in Chinese asthma patients. Chest,2009,135(5):1181-1185. |